Defining Progression in Metastatic Kidney Cancer
3 Views
administrator
06/26/23
Panelists Robert A. Figlin, MD; Michael R. Harrison, MD; David I. Quinn, MBBS, PhD; and Eric Jonasch, MD, discuss defining clinical progression and optimizing use of VEGF TKI therapy to achieve the highest dose intensity before switching in patients with metastatic kidney cancer.
-
Category
Show more
Facebook Comments
No comments found